Xtalks Life Science Podcast

Xtalks
  • 5.0 (1)
  • Life Sciences
  • Updated Weekly

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

  1. 1d ago ·  Video

    What’s Next in Cardiometabolic Disease Drug Development: Obesity, MASH and Beyond with MetaVia’s Hyung Heon Kim

    In this week’s episode of the Xtalks Life Science Podcast, host Vera Kovacevic, Editor-in-Chief at Xtalks, spoke with Hyung Heon Kim, CEO of MetaVia, a clinical-stage biotechnology company developing treatments for cardiometabolic diseases. Mr. Kim discusses the evolving cardiometabolic disease landscape, including the connections between obesity, diabetes, liver disease and cardiovascular risk. He shares his perspective on how obesity care has changed in recent years, where unmet needs remain and how priorities such as muscle preservation, metabolic health and long-term durability are shaping the next stage of drug development. The conversation also explores MASH, a complex liver disease closely linked to metabolic dysfunction. Mr. Kim discusses why MASH remains difficult to diagnose, study and treat, and why broader treatment strategies may need to address underlying drivers such as insulin resistance, inflammation and lipid metabolism. Mr. Kim also explores the challenges of designing and conducting clinical trials in obesity and MASH. He shares his perspective on where the cardiometabolic field is headed and what biotech leaders should consider when working in fast-moving, highly competitive therapeutic areas. Tune in to learn more about the future of obesity, MASH and cardiometabolic disease treatment. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    26 min

  2. May 27 ·  Video

    How Real-World Evidence Is Shaping Inclusive Clinical Trials with Takeda CMO Dr. Awny Farajallah

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Awny Farajallah, MD, Chief Medical Officer at Takeda, about the growing role of real-world evidence in improving clinical trial inclusivity and diversity. Also hear Dr. Farajallah discuss innovations in diseases such as narcolepsy type 1 and polycythemia vera, and how new technologies are transforming healthcare data into actionable insights. With over two decades of experience in the healthcare industry, Dr. Farajallah has led numerous medical affairs teams and contributed to the development and commercialization of therapeutics in oncology and other disease areas, including rare disease, hematology, neuroscience and immunology. Prior to his current role, Dr. Farajallah served as the Head of Global Medical Affairs for Oncology at Takeda, and held global, regional and local roles at Ipsen and Bristol Myers Squibb. Tune in to hear about how real-world evidence is driving more inclusive clinical trials, shaping patient-centered care and accelerating access to treatments. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    38 min

  3. May 20 ·  Video

    Stem Cell Therapies for Degenerative Disc Disease and More with BioRestorative’s Lance Alstodt

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Lance Alstodt, CEO, BioRestorative & Francisco Silva, Chief Scientist & VP, R&D, BioRestorative Inc. (NASDAQ:BRTX), a regenerative medicine company developing stem cell-based therapies and products. The company’s clinical programs target critical healthcare needs, including degenerative disc disease and metabolic disorders. Lance Alstadt has over 25 years of experience in leading medical technology and lifesciences companies in operations, capital raising activities, strategy and mergers and acquisitions. Mr. Alstodt has deep experience in the orthopedic and spine sectors. Mr. Alstodt was the Founder and CEO of MedVest Consulting Corporation an investment fund that focuses on healthcare, and previously served at Bank of America Merrill Lynch, and spent seven years in M&A at JP Morgan Chase. Mr. Alstodt has a BA in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing. Tune in to hear about the evolving landscape of regenerative medicine and the promise and challenges of stem cell-based therapies in treating chronic conditions like degenerative disc disease. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    38 min

  4. May 13 ·  Video

    New Blood Test for Early Alzheimer’s Detection with FNIH’s Dr. Alessio Travaglia

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Alessio Travaglia, PhD, Neuroscientist and Director of Translational Science at the Foundation for the National Institutes of Health (FNIH). New findings from a study published in Nature Medicine suggest that a single blood test may be able to predict the onset of Alzheimer’s symptoms within a three- to four-year period. Dr. Travaglia discusses how the test works, what it reveals about the earliest stages of disease and why identifying patients before symptoms appear could transform clinical trials and therapeutic development. Dr. Travaglia has 15 years of experience in basic and translational neuroscience in academia, non-profit, management consulting and venture philanthropy. Tune in to learn more about the new test and how it could transform the early detection of Alzheimer’s disease. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    31 min

  5. May 6 ·  Video

    Targeting Ischemic Disease with DiaMedica CEO Rick Pauls

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke Rick Pauls, President and CEO of DiaMedica Therapeutics (Nasdaq: DMAC), a company advancing multiple programs in challenging vascular conditions driven by ischemia, including preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). DiaMedica’s therapeutic approach in ischemia-based diseases centers on a recombinant form of the KLK1 protein, which plays a key role in regulating blood flow, reducing inflammation and supporting vascular health. Rick Pauls has served as President and CEO of DiaMedica since 2009 and has been a board member since 2005, including as Chair from 2008 to 2014. Previously, he co-founded and led CentreStone Ventures, an early-stage life sciences venture capital fund, worked as an analyst at Centara Corporation and specialized in asset-backed securitization and structured finance at General Motors Acceptance Corporation. He has also served on the boards of several public and private companies. Rick received his BA in Economics from the University of Manitoba and his MBA in Finance from the University of North Dakota. Tune in to hear about a novel therapeutic approach to treating ischemia-driven diseases like stroke and preeclampsia. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    30 min

  6. Apr 29 ·  Video

    Why Copyright Matters in Life Sciences in the Age of AI: Featuring Neal Dunkinson of Copyright Clearance Center

    In this special episode of the Xtalks Life Science Podcast, part of our Breakthrough with Dr. Corey Stanton series, host Dr. Corey Stanton speaks with Neal Dunkinson, Sr. Director of Solution Sales at Copyright Clearance Center (CCC), about why copyright and licensing are becoming mission-critical in modern life sciences research, particularly in the era of AI. Life sciences teams both generate and consume vast amounts of scientific literature, clinical data and third-party content. As Neal explains, copyright and licensing are no longer back-office considerations; they are central to enabling compliant collaboration, reducing information silos and supporting confident decision-making across R&D, medical affairs and regulatory teams. In this episode, Neal discusses the most common challenges organizations face when managing scientific literature and internal knowledge workflows, and how those challenges evolve as companies grow from early-stage biotechs into global enterprises. He highlights where compliance risks and information silos typically emerge in real-world research environments and how structured licensing strategies can help mitigate them. The conversation also explores how CCC’s approach to “making copyright work” translates into practical value for scientists and knowledge workers: removing friction from access to content while ensuring proper rights management behind the scenes. As AI-driven analytics and generative tools become embedded in life sciences workflows, new copyright considerations are emerging. Neal explains how CCC supports responsible AI development by enabling lawful access to high-quality content while ensuring that publishers and creators are fairly compensated. He shares his perspective on what “responsible AI” means in scientific research and how licensing frameworks will likely evolve as AI adoption accelerates. Neal joined CCC in January 2025 and brings 20 years of experience in informatics solutions for the life sciences R&D market. Over the course of his career, he has held roles at Thomson Reuters, Accelrys/Biovia and SciBite/Elsevier, where he helped scale SciBite from a four-person startup through its acquisition and integration into Elsevier. At CCC, he focuses on licensing and content workflow solutions tailored to the needs of life sciences organizations, aligning product capabilities with complex research and compliance requirements. Tune in to learn how forward-looking content and licensing strategies can help life sciences organizations future-proof their research operations while advancing compliant, AI-enabled discovery. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    55 min

  7. Apr 22 ·  Video

    Neuromodulation and Nerve Ablation for Chronic Pain with NeuroOne CEO Dave Rosa

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Dave Rosa, CEO, NeuroOne Medical Technologies Corporation, a company developing minimally invasive diagnostic and therapeutic electrodes employed in nerve ablation as well as neuromodulation devices to treat conditions such as epilepsy and chronic pain and enable drug delivery into the brain. Mr. Rosa is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc. and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards and has raised more than $200M in the capital markets.  Mr. Rosa holds an MBA from Duquesne University and a Bachelor of Science (BSc) in Commerce and Engineering from Drexel University. Tune in to learn about advancements in neuromodulation and nerve ablation for chronic pain. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    42 min

  8. Apr 15 ·  Video

    Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell

    In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, a biotechnology company advancing the first off-the-shelf bone marrow therapy derived from deceased organ donors. The treatment is designed to address longstanding clinical and logistical challenges in allogeneic bone marrow transplantation. Kevin Caldwell has led Ossium Health in building more than 50 strategic partnerships with biopharmaceutical companies and helped secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to founding Ossium, Kevin served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors, and prior to that, served as a Senior Investment Associate at Bridgewater Associates where he did quantitative research for the firm’s global macro investments. Kevin holds degrees in Physics and Economics from MIT and a JD from Harvard Law School. Tune in to learn about how about the landscape of cell therapy and allogeneic transplantation, including the translation of off-the-shelf cellular therapies into clinical practice and how emerging models could reshape bone marrow transplantation workflows. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    37 min
See All (255)

About

This Life Science focused podcast brings together Xtalks editorial staff to share insights into the latest B2B industry news. Xtalks connects professionals in the life science, medical device, and food industries with useful content like webinars, job opening, articles and virtual meetings.

Information

  • Creator
    Xtalks
  • Years Active
    2021 - 2026
  • Episodes
    255
  • Rating
    Clean
  • Copyright
    © 2024 Honeycomb Worldwide Inc.
  • Show Website
    Xtalks Life Science Podcast

You Might Also Like